Romania HIV Therapeutics Market Analysis Report [2022-30]

Romania HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Romania HIV therapeutics market will reach a value of $xx Mn from $39.9 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Terapia, Biofarm, and Farmexim. The market is driven by government policies, funding and organizations’ initiatives for management of HIV infections in the country. The HIV therapeutics market in Romania is segmented by type, product, and geography, end user and distribution channel.

ID: IN10ROPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Vishwa Modhia

Buy Now

Romania HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Romania HIV therapeutics market will reach a value of $xx Mn from $39.9 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

The nation of Romania is situated at the meeting point of Central and South-eastern Europe. According to the most recent WHO data, HIV/AIDS-related deaths in Romania reached 500 in 2020. With a death rate for HIV/AIDS of 1.22 per 100,000 people when adjusted for age, Romania is ranked 114 in the world.

With 19000 HIV cases in 2020, Romania's adult prevalence of HIV/AIDS was 0.2% in 2021, ranking 103rd globally. NGOs like UNOPA (the National Union of Organizations for People Affected by HIV/AIDS) provide HIV control and management in Romania. Healthcare cost Romania 6.3% of its GDP in 2019.

romania HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Romanian government has taken an active role in combating the HIV epidemic and has put in place a number of programs to increase access to testing and care for people living with HIV. Additionally, there has been an increase in cooperation between the public and private sectors in Romania to support the provision of care and antiretroviral medication for people living with HIV. This can drive the market for HIV therapeutics in Romania.

Market Restraints

Despite improvements in combating the HIV epidemic, stigma and discrimination against people who have the virus continue to be major obstacles to getting tested and receiving treatment, including antiretroviral drugs. Financial limitations, such as the price of antiretroviral medications and related laboratory tests, could also restrict some Romanians living with HIV from receiving treatment.

Competitive Landscape

Key Players

Farmexim S.A. (ROU)
Biofarm S.A. (ROU)
Terapia S.A. (ROU)
Antibiotice S.A. (ROU)
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline

Healthcare Regulations and Reimbursement Policies

The National Agency for Medicines and Medical Devices (NAMMD) is the principal regulatory body in charge of monitoring the approval and control of HIV therapeutics in Romania. For use in Romania, new drugs must be evaluated and approved by the NAMMD, which is also in charge of ensuring their efficacy and safety after approval. The organization also collaborates with other governmental organizations to guarantee that patients have access to antiretroviral therapy (ART), one of the most potent HIV treatments available. The Ministry of Health and the Romanian Society for the Study of AIDS, in addition to the NAMMD, play significant roles in combating the HIV epidemic and ensuring that those living with the virus have access to effective treatments.

The National Health Insurance Fund (CNAS), the main provider of health insurance for the Romanian population, insures access to antiretroviral therapy (ART) for the treatment of HIV in that country. The cost of ART for people with HIV, including the price of medications and lab tests, is covered by the CNAS. Programs are in place to support people who might have trouble getting access to treatment, like those from marginalized communities.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.